These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15317405)

  • 1. Pharmacoeconomics of thrombosis management.
    Hawkins D
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):95S-99S. PubMed ID: 15317405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic considerations in the prevention and treatment of venous thromboembolism.
    Hawkins D
    Am J Health Syst Pharm; 2004 Dec; 61(23 Suppl 7):S18-21. PubMed ID: 15597575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
    Tran AH; Lee G
    Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
    Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
    Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing, preventing, and treating venous thromboembolism: evidence-based approaches.
    Nutescu EA
    Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S5-13. PubMed ID: 17519445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
    Turpie AG; Bauer KA; Eriksson BI; Lassen MR
    Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
    Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
    J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
    Nijkeuter M; Huisman MV
    Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
    Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
    Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
    Spruill WJ; Wade WE; Leslie RB
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):539-43. PubMed ID: 15389119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
    Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
    Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
    Sullivan SD; Kwong L; Nutescu E
    Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness analysis of enoxaparin for the prophylaxis of venous thromboembolism in major orthopedic surgery patients].
    Brosa Riestra M; Rubio-Terrés C; Nadipelli V; Casado Collado A; Martínez Brotons F
    Farm Hosp; 2003; 27(4):210-8. PubMed ID: 12966450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
    Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
    Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery.
    Sullivan SD; Kahn SR; Davidson BL; Borris L; Bossuyt P; Raskob G
    Pharmacoeconomics; 2003; 21(7):477-96. PubMed ID: 12696988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
    Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
    Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for extended prophylaxis in the setting of orthopedic surgery.
    Dobesh PP
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):73S-81S. PubMed ID: 15317402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
    Turpie AG
    Int J Clin Pract; 2004 May; 58(5):483-93. PubMed ID: 15206506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.